Eris Lifesciences Ltd., an Indian branded formulations manufacturing company, has announced that a manufacturing unit in its Ahmedabad campus has received approval from ANVISA, which is Brazil’s national health regulatory agency.

This approval follows a successful inspection conducted by the agency in May 2025 and enables Eris to enter Brazil, the largest pharmaceutical market in South America.

A company spokesperson said that this approval by a stringent regulatory authority like Anvisa is a tangible endorsement of the GMP and quality systems at the company’s manufacturing facilities. The said manufacturing facility has been successfully inspected by various other regulatory agencies earlier in the year.

Eris manufactures a wide range of prescription products across several dosage forms including oral solids, oral liquids, softgels, ointments, sprays and gels, sterile injectables and biologics in its 6 manufacturing facilities, and markets these products across India.

Eris has reported a revenue of INR 2,894 crore in FY25. The company has diversified its presence across geographies, technologies and therapeutic areas with an investment of about INR 4,000 crore over the last 3 years.